98%
921
2 minutes
20
Histotripsy is a novel, noninvasive, non-thermal technology invented in 2004 for the precise destruction of biologic tissue. It offers a powerful alternative to more conventional thermal or surgical interventions. Using short-pulse, low-duty cycle ultrasonic waves, histotripsy creates cavitation bubble clouds that selectively and precisely destroy targeted tissue in a predefined volume while sparing critical structures like bile ducts, ureters, and blood vessels. Such precision is of value when treating tumors near vital structures. The FDA has cleared histotripsy for the treatment of all liver tumors. Major medical centers are currently spearheading clinical trials, and some institutions have already integrated the technology into patient care. Histotripsy is now being studied for a host of other cancers, including primary kidney and pancreatic tumors. Preclinical murine and porcine models have already revealed promising outcomes. One of histotripsy's primary advantages is its non-thermal mechanical actuation. This feature allows it to circumvent the limitations of heat-based techniques, including the heat sink effect and unpredictable treatment margins near sensitive tissues. In addition to its non-invasive ablative capacities, it is being preliminarily explored for its potential to induce immunomodulation and promote abscopal inhibition of distant, untreated tumors through CD8+ T cell responses. Thus, it may provide a multilayered therapeutic effect in the treatment of cancer. Histotripsy has the potential to improve precision and outcomes across a multitude of specialties, from oncology to cardiovascular medicine. Continued trials are crucial to further expand its applications and validate its long-term efficacy. Due to the speed of recent developments, the goal of this review is to provide a comprehensive and updated overview of histotripsy. It will explore its physics-based mechanisms, differentiating it from similar technologies, discuss its clinical applications, and examine its advantages, limitations, and future.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12346746 | PMC |
http://dx.doi.org/10.3390/cancers17152548 | DOI Listing |
Pharmaceutics
July 2025
Joint Department of Physics, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, UK.
: Boiling histotripsy (BH) uses high-amplitude, short-pulse focused ultrasound to disrupt tissue mechanically. Oncolytic virotherapy using reovirus has shown modest clinical benefit in pancreatic cancer patients. Here, reovirus and BH were used to treat pancreatic tumours, and their effects on the immune transcriptome of these tumours were characterised.
View Article and Find Full Text PDFAm Surg
August 2025
Surgical Oncology, Swedish Health Services, Seattle, WA, USA.
Hilar cholangiocarcinoma (HCCA) is a rare, aggressive cancer often diagnosed at an unresectable stage. Patients commonly require systemic therapy and biliary stenting to manage symptoms and maintain liver function. Histotripsy is a novel, non-invasive, mechanical ablation technique recently FDA-approved for liver tumors.
View Article and Find Full Text PDFUltrason Sonochem
August 2025
Department of Mathematics and Computer Science, Faculty of Science, Menoufia University, Shebin El-Koom 32511, Egypt; Menoufia National University, Menoufia, 6162101, Egypt.
In this review, the theoretical studies are presented for the microcavitation bubble dynamics problems, which mainly depend on the microcavitation models, such as the Rayleigh-Plesset model, the Church model, the diffusion-concentration model, and the Keller-Miksis model in biological systems. The various solutions to these models, which were formulated based on basic mathematical and physical concepts, are schematically presented. Moreover, these models are employed in many different physical problems, such as the treatment of cancerous tumours via a technique known as histotripsy and lipid shells of membrane cells, that employ focused ultrasonic therapy as a non-invasive tissue ablation method.
View Article and Find Full Text PDFCurr Oncol
August 2025
Department of Surgery, University of Virginia Health System, Charlottesville, VA 22903, USA.
Sarcomas are tumors of mesenchymal origin that are generally resistant to systemic therapies and prone to local recurrence despite current multimodal treatment approaches. Focused ultrasound (FUS) is a noninvasive therapeutic technology that may enhance standard treatment strategies for primary solid malignancies. FUS exerts its effects through diverse mechanisms, including high-intensity focused ultrasound (HIFU) thermal ablation, histotripsy, sonodynamic therapy, immunomodulation, and hyperthermia-enhanced drug delivery.
View Article and Find Full Text PDFJ Vasc Interv Radiol
September 2025
Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California, San Diego, San Diego, CA.